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Available online 29 March 2017In Parkinson's disease (PD) depletion of dopamine in the nigro-striatal pathway is a main pathological hallmark
that requires continuous and focal restoration. Current predominant treatment with intermittent oral adminis-
tration of its precursor, Levodopa (L-dopa), remains the gold standard but pharmacological drawbacks trigger
motor ﬂuctuations and dyskinesia. Continuous intracerebroventricular (i.c.v.) administration of dopamine previ-
ously failed as a therapy because of an inability to resolve the accelerated dopamine oxidation and tachyphylaxia.
We aim to overcome prior challenges by demonstrating treatment feasibility and efﬁcacy of continuous i.c.v. of
dopamine close to the striatum. Dopamine prepared either anaerobically (A-dopamine) or aerobically (O-dopa-
mine) in the presence or absence of a conservator (sodiummetabisulﬁte, SMBS) was assessed upon acute MPTP
and chronic 6-OHDA lesioning and compared to peripheral L-dopa treatment. A-dopamine restored motor func-
tion and induced a dose dependent increase of nigro-striatal tyrosine hydroxylase positive neurons inmice after
7 days of MPTP insult that was not evident with either O-dopamine or L-dopa. In the 6-OHDA rat model, contin-
uous circadian i.c.v. injection of A-dopamine over 30 days also improved motor activity without occurrence of
tachyphylaxia. This safety proﬁle was highly favorable as A-dopamine did not induce dyskinesia or behavioral
sensitization as observed with peripheral L-dopa treatment. Indicative of a new therapeutic strategy for patients
suffering from L-dopa related complications with dyskinesia, continuous i.c.v. of A-dopamine has greater efﬁcacy
in mediating motor impairment over a large therapeutic index without inducing dyskinesia and tachyphylaxia.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Parkinson's disease
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Treatment–disease modifying effect1. Introduction
Parkinson's disease (PD) is the secondmost frequent neurodegener-
ative disorder worldwide. The loss of dopamine through denervation in
the striatum as a result of progressive neuronal degeneration in the
substantia nigra pars compacta (SNpc), is the primary neurotransmitter
marker of the disease (De Lau and Breteler, 2006). Since dopamine does
not cross the digestive mucosa or the blood brain barrier, its lipophilicricular; L-dopa, levodopa;MPTP,
A, 6-hydroxydopamine; PD,
bstantia nigra pars compacta.
logie Médicale, Université Lille
ect.com).
. This is an open access article underprecursor L-dopa has been employed and remains the pivotal oral med-
ication (Chaudhuri and Schapira, 2009). However, after persistent use
over several years, many pharmacokinetic drawbacks contribute to
the occurrence of motor ﬂuctuations and dyskinesia (Fahn and
Parkinson study group, 2005). Indeed L-dopa has a short half-life,
limittped and variable reabsorption through the digestive and blood
brain barriers and potentially harmful peripheral distribution. More-
over, L-dopa requires the aromatic L-amino acid decarboxylase for the
synthesis of dopamine, which declines in the striatum with disease
progression (Ciesielska et al., 2015).
Under normal conditions, dopaminergic neurons of the SNpc gener-
ate a short phasic discharge ﬁring pattern. The frequency and duration
of this pattern embeds them in the tonic low-frequency background
range and maintains the striatal dopamine concentration at a relatively
constant level (Paladini and Roeper, 2014). However, in the dopamine-
depleted state relevant to PD, intermittent oral doses of L-dopa canthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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turn contribute to dysfunctional dopaminergic pathways. Thus, contin-
uous dopamine administration is considered more physiologically ap-
propriate by preventing oscillations in neurotransmitter concentration
(Olanow et al., 2006; Gershanik and Jenner, 2012). De Yebenes et al.
(1987) previously demonstrated that intracerebroventricular (i.c.v.)
administered dopamine with an anti-oxidant adjuvant (sodium
metabisulﬁte; SMBS) transiently improved motor handicap and
increased dopamine in rat brains with unilateral neurotoxin 6-
hydroxydopamine (6-OHDA)-induced damage as well as 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxicated monkeys. The
clinical feasibility of this administrative route has been supported by
two PD patient case reports of dopamine infusion to the frontal ventri-
cle, whereby a reduction in motor handicap was observed (Venna et
al., 1984; Horne et al., 1989). However, both preclinical and clinical re-
ports also highlight two overriding problems that prevented further de-
velopment; (i) occurrence of tachyphylaxia and (ii) oxidation of
dopamine causing enhanced dopamine metabolism and oxidative
stress.
Dopamineoxidation can be limited bypreparing, storing and admin-
istering dopamine in very low oxygen conditions. In addition, greater
advances in programmable pumps now minimize tachyphylaxia by
allowing administration of a lower effective dopamine dose in accor-
dance with the circadian cycle. The purpose of this study is to demon-
strate that continuous circadian i.c.v. administration of dopamine close
to the striatum is feasible, efﬁcient and safe in mouse and rat models
of PD, supporting clinical development of this strategy to be revisited
in PD patients with L-dopa related complications with dyskinesia.
2. Material and methods
2.1. LUHMES cells
Lund human mesencephalic (LUHMES) cells (gift from Pr. Marcel
Leist; CAAT, University of Konstanz, Germany) were grown for 2 days
in differentiation medium (advanced DMEM/F12, 1 × N2 supplement,
2 mM L-glutamine, 1 mM cAMP, 1 μg/ml tetracycline and 2 ng/ml re-
combinant GDNF) before seeding in 6 or 24 well plates and grown for
a further 3 days before treatment. See supplementary material for
details.
After 5 days of differentiation, LUHMES cells were treated with 1-
methyl-4-phenylpyridinium (MPP+; 5 μM) for 24 h (h) before expo-
sure to dopamine or L-3,4-dihydroxyphenylalanine (L-dopa) (Sigma Al-
drich, St Louis, MO, USA) for a further 24 h. Viability was measured on
10,000 cells by ﬂow cytometry (CANTO II) using propidium iodide
(0.5 μM) and analysed with DIVA software (BD Biosciences, Le pont de
Claix, France).
2.2. Rodent neurotoxic models
All experimentswere carried out in accordancewith the recommen-
dations for the care and use of laboratory animals (FELASA) as well as
European Directive 86/609-2010/63/UE guidelines for animal experi-
mentation. Protocols were approved by an Ethical Committee (Nord-
Pas-de-Calais; CEEA75) to induce MPTP neurotoxicity on 5 month old
C57Bl/6 J mice (Ethical permit number: CEEA102012) or 6-OHDA neu-
rotoxicity in 5 month old Wistar rats (Ethical permit number: CEEA
262011 and CEEA2016020911207601). Animals were group-housed
(10 mice or 5 rats per cage) and a habituation period of 7 days after
transportation was respected before any experimental manipulation
was carried out. All surgery was performed under anesthesia and all
efforts were made to minimize suffering.
Experimental procedures for obtaining the MPTP mice and 6-OHDA
rat models have been previously described (Laloux et al., 2012). Brieﬂy,
mice received four intraperitoneal injections (with 2 h intervals) of ei-
ther saline solution only or 20 mg/kg MPTP (Sigma Aldrich, St Louis,MO, USA). The rats received one cerebral unilateral injection of vehicle
or 8 μg 6-OHDA (Sigma Aldrich, St Louis, MO, USA) through stereotaxic
surgery to the right medial forebrain bundle.
2.3. Treatment parameters for rodent models
L-dopa methyl ester hydrochloride (Sigma Aldrich, St Louis, MO,
USA) was extemporaneously prepared in saline with 12 mg/kg
Benserazide, independent of L-dopa dose (Cenci and Lundblad, 2007).
During the treatment regime L-dopawas administered intraperitoneally
(i.p.) twice a day at doses previously reported for mice and rats
(Espadas et al., 2012; Fornai et al., 2000). Anaerobia-dopamine (A-do-
pamine, Patent #WO2015173258 A1) was prepared by dissolving in
saline (0.9% NaCl, pH 7.4) before the osmotic pump was ﬁlled and con-
nected to a brain infusion cannula under an atmosphere that contained
5% hydrogen, 5% carbon dioxide and 90%nitrogen (BACTRONanaerobic/
environmental chamber). Before stereotaxic surgery, osmotic pumps
were primed under anaerobia for over 4 h at 37 °C. The stability of the
A-dopamine solution in osmotic pump at 37 °C was checked for up to
30 days using an HPLC assay for dopamine (data not shown).
Treatment over 7 days began one week post MPTP or saline injec-
tions in mice. Mice were divided into 13 experimental groups; Saline
only, MPTP only, MPTP + A-dopamine (3 to 5 different doses), MPTP
+ O-dopamine (3 different doses), and MPTP + L-dopa (3 different
doses). A- or O-dopamine was administered continuously by i.c.v.
(1 μl/h; 24 h/24 h) after surgical cannula-pump (ALZET 2001) implanta-
tion in the right lateral ventricle (see supplementalmaterial for details).
L-dopa was administered by i.p. twice a day over the same treatment
period.
Chronic dopamine treatments (30 days) on rats began 3weeks after
unilateral 6-OHDA or saline cerebral injection. Only 6-OHDA rats
displaying N5 turns/min in the Apomorphine-induced rotation test
were used in the study (75% of the rats). Rats were divided into 6 exper-
imental groups; saline only, 6-OHDA only, 6-OHDA + A-dopamine (3
different doses) and 6-OHDA + L-dopa. After surgical cannula-pump
(programmable IPRECIO® SMP200 pumps) implantation on the 6-
OHDA lesion side (see supplemental material for details) A-dopamine
was administered to the right lateral ventricle by i.c.v. at a rate of 3 μl/h
for 16 h out of 24 h (Zeitgeber time 13 to 5). Rats were housed in a
12 h light/12 h dark cycle and the implanted pump was set to deliver
dopamine over 16 h, predominantly during the active (dark) phase of
the rat while it is awake. However this also included part of the resting
(light) phase to allow behavioral assessments under treatment (see
Supplemental image 1 for the time delivery settings). L-dopa was
administered by i.p. twice a day over the same treatment period.
2.4. Behavioral assessment
2.4.1. Actimetry
Spontaneous motor activity in mice and rats was recorded by an
actimeter (Panlab, Barcelona, Spain) over 10 min (Laloux et al., 2012).
This apparatus and the associated Actitrack software allowed distance
travelled, speed and rearing behavior to be measured based on infrared
beams obstructions.
2.4.2. Drug-induced rotation test
To assess rotational asymmetry, contralateral rotations over 10 min
were counted 30min after ratswere subcutaneously (s.c.) injectedwith
apomorphine (APOKINON®; 0.5 mg/kg). Only nigro-striatal-lesioned
animals performing N5 turns/min were included in the experimental
cohorts as these have N80% depletion of striatal dopamine terminals
(Francardo et al., 2011).
2.4.3. Cylinder test
Rats performed the cylinder test (Schallert et al., 2000) to evaluate
spontaneous forelimb lateralization. The number of vertical forepaw
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assessed during 3 min.2.4.4. Stepping test
The Stepping test (Olsson et al., 1995) is designed to monitor fore-
limb akinesia. Rats were gently dragged by the hindquarters across a
bench over a distance of 0.90 m in 5 s. Supportive leg adjustments by
the rat were counted over 3 consecutive trials.2.4.5. Treatments-induced dyskinesia assessment
The principles and classiﬁcations of dyskinesia have been standard-
ized and well-described for the rat (Cenci and Lundblad, 2007). Follow-
ing the injection of L-dopa or during treatment, dyskinesia analysis
consisted of scoring rat motor behavior for 1 min every 20 min over
3 h. Based on duration and persistence of the dyskinetic behavior during
the 1-min observation period, abnormal involuntarymovements (AIM)
were divided into locomotive, axial, forelimbs and orolingual subtypes.
For each subtype, a score from 0 to 4 was given to culminate into an
overall dyskinesia score for each rat.2.5. Nigro-striatal tyrosine hydroxylase staining and analysis
After treatment and behavioral analysis, mice and rats were
sacriﬁced and 4% paraformaldehyde perfused brains were microscopi-
cally sectioned by cryostat for tyrosine hydroxylase immunochemistry
(1:1000; Chemicon International, CA, USA). SN and striatal terminal
THr + neurons were counted by stereological analysis software
(Explora Nova, La Rochelle, France) (See supplemental material for
details).2.6. Striatum analysis by HPLC
Striatal samples were homogenized (0.1 M perchloric acid, 2.6 mM
sodium disulﬁte, 0.7 mM EDTA, 25 ng/ml 3,4-dihydroxybenzilamine)
before supernatants were separated by HPLC using a Chromsystems
column for Dopamine, DOPAC and 5-cysteinyl-dopamine or an
Uptisphere column for HVA. Glutathione status (i.e. GSSG/GSH) was
also determined chromatographically after derivatization with
orthophthalaldehyde was accomplished using isocratic elution on a
Symmetry Shield C18 column (Waters SAS, France) (See supplemental
material for details).Fig. 1. Dose-related effects of dopamine on LUHMES dopaminergic neurons. Overall LUHME
Signiﬁcant differences * vs. saline condition, # vs.MPP+ condition, § between the dopamine a2.7. Statistical analysis
All data were expressed as mean ± SEM, mostly as a percentage
from the saline or vehicle control group. For all parameters, a one-way
ANOVA was used to assess group effect, followed by LSD Fisher post
hoc test. If data did not follow a Gaussian distribution, a Kruskal-Wallis
variance analysis was performed, followed by Mann-Whitney post hoc
test. The threshold for statistical signiﬁcance was set to p b 0.05. All sta-
tistical analyses were performed with IBM SPSS Statistics (Version 20).
3. Results
3.1. Dose-related effects of dopamine on dopaminergic neurons in vitro
In order to eliminate the possibility of dopamine being systematical-
ly deleterious, we demonstrated in vitro that low tomoderate dopamine
dose (≤3 μM) prevented MPP+ induced neurotoxicity whereas L-dopa
was substantially less efﬁcient (Fig. 1). Conversely, high doses of either
dopamine or L-dopa (10- to 100-fold higher) hadmoderate to noneuro-
protective effect and a very high dose of dopamine (1000-fold higher)
increased cell death. The optimal window of neuroprotection for both
dopamine and L-dopa was determined to be 0.05–0.2 μM.
3.2. Deleterious effect of dopamine oxidation avoided by anaerobic prepa-
ration of dopamine in vivo
Continuous i.c.v. administration of 240 μg/day O-dopamine induced
dopamine oxidation even in the presence of SMBS. This was visually de-
tectable via a brown to black discoloration of the brain's ventricular
walls. Despite an improvement in motor activity compared to sham
treatedmice (Fig. 2A), addition of O-dopamine lowered the count of ty-
rosine hydroxylase positive (TH-ir+) neurons in SNpc (Fig. 2B). A re-
duction in the administered O-dopamine dose (120 μg/day) negated
the changes to TH-ir + neuron counts, but strong discoloration of the
ventricular walls was still observed in N65% of the mice.
In order to avoid the use of SMBS, due to its poor anti-oxidant
properties with additional detrimental effects (Nair et al., 2003), an A-
dopamine preparation protocol was developed to maintain the neuro-
transmitter in an anaerobic environment throughout the ﬁlling and
pump priming procedures. Similar to O-dopamine with SMBS, high A-
dopamine dose (240 μg/day) without SMBS improved motor impair-
ment but was still deleterious to SNpc TH-ir + neurons (Fig. 2B).
However, A-dopamine at 120 μg/day without SMBS improved motor
activity without neuropathology to the nigro-striatal pathwaysS viability was greater after A-dopamine compared to L-dopa treatment (0.01–300 μM).
nd L-dopa conditions, p b 0.05 (Mann-Whitney comparison test).
Fig. 2. Neuroprotection of nigro-striatal pathway and functional recovery induced by cerebral A-dopamine infusion in MPTP mice. Distance covered in actimetry arena (A) and TH-ir
+ neuronal count in SNpc (B) was measured in MPTP mice after 7 days of dopamine treatment, either supplemented with SMBS or prepared anaerobically. To determine the optimal
dose of each treatment on motor function post-MPTP insult, distance covered (C) and mean speed (D) within the actimetry arena was assessed after i.p. L-dopa (25-100 mg/kg/day) or
i.c.v. dopamine prepared anaerobically (A-dopamine)(40-120 μg/day) or aerobically (O-dopamine) (60-120 μg/day). Neuropathological outcomes were also assessed within the same
parameters by measuring ipsilateral and contralateral TH-ir + optical density in dorsal striatum (E) and TH-ir + neuronal counts in SNpc (F). Data are expressed in percentage from
saline mice, means ± SEM (n= 6/group for A&B, 12/group for C&D, 8/group for E&F). Signiﬁcant differences * vs. saline mice, # vs. untreated MPTP mice, p b 0.05 (one-way ANOVA
and LSD Fisher post-hoc tests or Mann-Whitney comparison test).
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tricular walls was observed in some mice (~30%).
3.3. Functional recovery induced by A-dopamine
The safety proﬁle of A-dopaminewas further studied inMPTP-treat-
ed mice using a broad dose range (40–120 μg/day) and compared to O-
dopamine (60–120 μg/day) and i.p. L-dopa (twice daily, 25–100 mg/day) (Fig. 2 C\\F). After 7 days, A-dopamine functionally re-
stored mean speed and distance covered by the mouse and had a
broader therapeutic index than peripheral L-dopa treatment (i.e. only
50 mg/kg/day L-dopa was beneﬁcial)(Fig. 2C–D). Dose-effect on SNpc
and striatal TH-ir + neuron survival by A-dopamine was u-shaped,
without hemispheric preference in the SNpc (Fig. 2 E–F). The increase
in TH-ir+neurons induced by A-dopamine at 60 and 80 μg/daywas de-
termined to be optimal whereas 120 μg/day also reversed TH-ir
28 C. Laloux et al. / Neurobiology of Disease 103 (2017) 24–31+terminal loss in striatum. Conversely, neither O-dopamine nor L-dopa
prevented reduced TH-ir counts after MPTP in the SNpc and striatum.
3.4. Diffusion and metabolism of A-dopamine within the brain
Lateral ventricular administration of 80 and 120 μg/day A-dopamine
demonstrated good diffusion into the ipsilateral striatum post MPTP in-
toxication. Similar results were observed upon peripheral L-dopa ad-
ministered at 50 and 100 mg/day, with 120 μg/day A-dopamine and
100 mg/day L-dopa having comparable maximal diffusion (Fig. 3A).
The reduction in DOPAC andHVAmetabolites caused byMPTP in the
striatum (75% loss) was signiﬁcantly restored by 60 to 120 μg/day of A-
dopamine and in a dose-dependent manner with L-dopa (Fig. 3B–C). Of
note, A-dopamine preferentially increased HVAwhereas L-dopa favored
aDOPAC increase, potentially revealing alternatemetabolismpathways.
As bilateral distribution from the lateral ventricle through the third
ventricle to both striatum is not evident in mice, A-dopamine did not
alter the contralateral striatal level of dopamine or metabolites (except
for the highest dose which signiﬁcantly increased HVA).
3.5. Changes to A-dopamine oxidative metabolism
The oxidative metabolism of dopamine was determined by 5-
cysteinyl dopamine; a glutathione-dependent covalent modiﬁcation ofFig. 3. Diffusion and metabolization of striatal A-dopamine. Within the striatum,
dopamine (A) 3,4 dihydroxyphenylacetic acid (DOPAC) (B) and homovanillic acid
(HVA) (C) were measured in each hemisphere after 7 days of L-dopa or anaerobic
dopamine (A-dopamine). Ipsilateral and contralateral represents the side in which i.c.v.
dopamine was infused. Data are expressed in percentage from saline mice, means ±
SEM (n = 6 animal per group). * vs. saline mice, # vs. untreated MPTP mice, p b 0.05
(one-way ANOVA and LSD Fisher post-hoc tests).dopamine quinones derived from dopamine oxidization (Chen et al.,
2008). Levels were not modiﬁed with doses of A-dopamine below 120
μg/day (i.e. ≤ 0.3 nmol/mg) or with the peripheral L-dopa treatment
(undetectable) (Suppl. Table 1). Glutathione was strongly oxidized
by MPTP intoxication (as indicated by low GSH/GSSG ratio) but the
GSH/GSSG ratio was signiﬁcantly increased by both A-dopamine and
L-dopa treatments. This suggested that both were equally protective in
regard to the redox state of dopaminergic neurons.
3.6. Lack of tachyphylaxia following chronic A-dopamine stimulation in 6-
OHDA rats
In 6-OHDA treated rats, A-dopamine was chronically administered
by i.c.v. for 30 days (16 h/day) at 3 doses (1, 2 and 3 mg/day). This re-
gime was compared behaviorally to peripherally administered L-dopa
(6 mg/kg twice daily) over the same time period. For A-dopamine,
‘stepping’ and the ‘cylinder’ tests were consistent with actimetry analy-
sis. At both 15 and 30 days post-neurotoxin injection, a dose response
effectwas observed for A-dopamine,whereby 1mg/daywas considered
ineffective, 2 mg/day restored the mean locomotive speed and distance
of the rat and 3mg/day induced over-activity (Fig. 4A–D). Observation-
ally, it was noted that differences between 2 and 3 mg/day at 15 days
were reduced after 30 days of treatment. As previously reported 6-
OHDA rats responded well to L-dopa treatment in all three motor tests
(Laloux et al., 2012) despite an over compensation after 30days of treat-
ment of the contralateral paw in the cylinder and stepping test (Fig. 4C
& D).
3.7. Lack of dyskinesia and dopaminergic sensitization following A-dopa-
mine stimulation
Chronic peripheral treatment with L-dopa (6 mg/kg twice daily for
30 days) induced a consistent and high dyskinesia score compared to
sham or 6-OHDA-treated rats (Table 1). However throughout the treat-
ment period, all doses of A-dopamine (1–3 mg/day) produced minimal
abnormal locomotive movements and dyskinesias was undetectable
(Video 1). Moreover, as previously reported (Bordet et al., 2000), by
the end of the 30 day treatment period behavioral dopaminergic sensi-
tization associated with dyskinesia was evident in L-dopa treatment
(Fig. 4E). Conversely, a reduced number of apomorphine-induced rota-
tions were observed with A-dopamine administration.
3.8. Good safety proﬁle of A-dopamine
Neither L-dopa or A-dopamine had supplementary deleterious ef-
fects on the remaining 10% TH-ir+neurons after ipsilateral 6-OHDA in-
jection (Fig. 4G &H). Highest doses of A-dopaminemay even have had a
positive impact (Fig. 4G). A signiﬁcant body weight gain was observed
in higher doses of A-dopamine and may be attributed to dopamine ef-
fect on motivation to eat (via its action on mesolimbic system) or an
orexigen effect (via the hypothalamic system). In L-dopa treated rats
this gain was reduced after 30 days compared to shams (Fig. 4F) and
could be associated with higher daily energy expenditure as a result
from the observed dyskinesias. No overall harmful effects could be at-
tributed to bodyweight changes and no anatomopathological alteration
of heart, liver, pancreas, spleen, kidney, spinal cord, eye, and brain were
observed after 30 days of either treatment.
4. Discussion
Results obtained in these three differentmodels of PD demonstrate a
promising therapeutic regime for A-dopamine treatment. In vitro, a pos-
itive effect of dopamine was observed on LHUMES cell survival. In vivo,
A-dopamine restoredmotor function and induced a dose dependent in-
crease of nigro-striatal tyrosine hydroxylase positive neuron survival in
mice after 7 days of MPTP insult, suggesting a strong safety proﬁle that
Fig. 4. Functional recoverywithout tachyphylaxia or dopaminergic sensitization following chronic circadian A-dopamine stimulation in 6-OHDA rats. 6-OHDA rats were administered i.p.
L-dopa (12mg/kg/day) or i.c.v. anaerobically prepareddopamine (A-dopamine; 1–3mg/day) andmotor skills assessed after 15 or 30 days. Distance covered (A) andmean speed (B) in the
actimetry arena aswell as right paw support in the cylinder test (C) and right step adjustment in the stepping test (D) were evaluated. All datawas compared to vehicle control set at 100%
within the actimetry arena (A&B) or 50% representing equal forelimb preference (C&D). For apomorphine induced rotation, measurements were taken immediately after 6-OHDA insult
but before treatment (D0) as well as 30 days after treatment (D30) in the same treatment parameters (E). Rat body weight gain during the 30 days of treatment (F) as well as TH-ir
+ optical density in dorsal striatum (ipsilateral and contralateral) (G) and TH-ir + neuronal count in SNpc (H) were also evaluated. All data are expressed in percentage from Vehicle
rats, means ± SEM (n = 10/group). Signiﬁcant differences * vs. vehicle rats, # vs. untreated 6-OHDA rats, p b 0.05 (one-way ANOVA and LSD Fisher post-hoc tests or Mann-Whitney
comparison test).
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model using 6-OHDA-lesioning, continuous circadian i.c.v. injection of
A-dopamine over 30 days also improved motor activity without occur-
rence of tachyphylaxia. Signiﬁcantly, A-dopamine did not induced dys-
kinesia or behavioral sensitization as observed with peripheral L-dopa
treatment.
Similar to L-dopa treatment in previous clinical and preclinical stud-
ies, inconsistencies are reported in the use of dopamine, whereby high
doses are described as neurotoxic (Hastings et al., 1996) but sub-toxic
concentrations have neuroprotective and neurotrophic effects (Jia etal., 2008). We conﬁrm that the positive impact of dopamine on TH-ir
+ neurons of the nigro-striatal pathways was predominantly depen-
dent on dose, but the oxidation state of dopamine is also paramount.
As well as illustrating that O-dopamine was detrimental to neurons,
higher A-dopamine concentrations in the presence of MPTP also in-
duced signiﬁcant neurotoxic 5-cysteinyl-DA production. However a
low A-dopamine dose promoted TH-ir + neuronal counts with no evi-
dence of oxidized dopamine.
To our knowledge, this is theﬁrst to describe such a SNpc and striatal
TH-ir + neuronal plasticity with dopamine administration. We suggest
Table 1
Lack of dyskinesia during cerebral infusion of A-dopamine in 6-OHDA rats.
The table differentiates dyskinesia scores (Limb, axial and orolingual) and abnormal invol-
untary movements (AIM) in locomotion each 20 min over 2 h. At 7, 15 and 30 days of
treatment, measurement began 30 min after i.p. L-dopa or during A-dopamine i.c.v. Data
are expressed inmeans± SEM (n=10 animal per group). Signiﬁcant differences * vs. un-
treated 6-OHDA rats, # vs.L-dopa treated 6-OHDA rats, p b 0.05 (non-parametric Kruskal-
Wallis variance analysis and Mann-Whitney comparison).
Exp
time
6-OHDA
rat
groups
Dyskinesia types Dyskinesias
score
Locomotive
AIM
Limb Axial Orolingual
D7 Vehicle 0 0 0 0 0
L-dopa 11.1 ±
1.99 *
8.4 ±
1.67 *
9.9 ± 1.66
*
29.40 ±
5.25 *
4.8 ± 1.39
*
A-DA 1
mg/d
0 0 0 0 1 ± 1 #
A-DA 2
mg/d
0 0 0 0 2.14 ± 0.91
A-DA 3
mg/d
0 0 0 0 5.4 ± 1.12
*
D15 Vehicle 0 0 0 0 0
L-dopa 12.2 ±
1.67 *
7.9 ±
1.38 *
10.9 ±
1.75 *
31.0 ± 4.63
*
6.1 ± 1.0 *
A-DA 1
mg/d
0 0 0 0 0.7 ± 0.7 #
A-DA 2
mg/d
0 0 0 0 1.56 ± 0.67
#
A-DA 3
mg/d
0 0 0 0 2.71 ± 1.02
#
D30 Vehicle 0 0 0 0 0
L-dopa 13.6 ±
2.03 *
8.6 ±
1.85 *
13.5 ±
2.15 *
35.7 ± 5.89
*
7.2 ± 1.33
*
A-DA 1
mg/d
0 0 0 0 1 ± 1 #
A-DA 2
mg/d
0 0 0 0 2.25 ± 1.31
#
A-DA 3
mg/d
0 0 0 0 0.6 ± 0.4 #
30 C. Laloux et al. / Neurobiology of Disease 103 (2017) 24–31that this could be explained by a culmination of events. Low A-dopa-
mine dose prevented TH stained neuronal death caused by synaptic in-
activity (Jeon et al., 1995), restored dopaminergic cell markers required
for maintained dopamine production (Datla et al., 2001), scavenged
rather than promoted ROS formation (Agil et al., 2006) and may have
enabled a switch in striatal neurons from a serotonergic to dopaminer-
gic phenotype (Carta et al., 2007).
A viable optimal therapeutic regime would be to continuously com-
pensate the deﬁcit in dopamine thatmediates neuronal communication
within the SNpc. A continuous non-pulsatile i.c.v. administration better
mimics the physiological released of dopamine caused by the tonic
background activity of SNpc neurons (Olanow et al., 2006). In animal
models of PD, several studies have proven the efﬁcacy of continuous do-
pamine infusion. Hargraves and Freed (1987) showed that striatal injec-
tion of 12 or 120 μg/day dopaminewith SMBS (during 13 days) reduced
locomotive abnormalities, whereas others studies conﬁrmed this result
with alternative administration parameters (e.g. i.c.v. injection, dose at
240 μg/day or time over 7 days) (De Yebenes et al., 1987; Kroin et al.,
1991). The ﬁrst human case report (Venna et al., 1984) described a
good tolerance to dopamine infusion over 1 year. A subsequent
human case report (Horne et al., 1989) supports our current data by il-
lustrating that long-term i.c.v. dopamine provides a smooth control of
motor symptoms. However until now, concerns regarding dopamine
oxidation and patient tachyphylaxia have restricted further develop-
ment. Of note, PD patients from previous studies received O-dopamine
and at the same dose throughout a 24 h cycle. Prior experience obtained
from theuse of an apomorphine pumpand duodopa®has identiﬁed the
need to differentiate between diurnal and nocturnal minimum efﬁcient
dose in order to avoid worseningmotor ﬂuctuations (Devos and French
DUODOPA study group, 2009; Drapier et al., 2016).
In summary, far frombeing deleterious,we observe thatwhen dopa-
mine levels and oxidative state are harnessed it can be beneﬁcial toneuron survival. Minimizing dopamine administrative dose, focusing
delivery location and restricting the oxidative states all had a positive
impact on the nigro-striatal pathways. Long-term i.c.v. of A-dopamine
using a circadian cycle also dramatically reduced the detrimental side
effects of the current therapeutic regime of L-dopa (i.e.L-dopa related
complications with dyskinesia).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2017.03.013.
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